Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

Neurofibromatosis Type 2 Clinical Trial

Official title:

A Single Arm, Monocenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01345136
• Other study ID #: 13-001492
• Status: Terminated
• Phase: Phase 2
• Start date: July 1, 2015
• Est. completion date: February 6, 2024

Study information

• Verified date: February 2024
• Source: Jonsson Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to determine if RAD001 treatment will shrink or slow the growth of the vestibular schwannoma(s) in Neurofibromatosis 2 (NF2) patients. Secondary objectives include determining if RAD001 treatment will improve hearing ability in NF2 patients. RAD001 is an oral drug that is approved by Food and Drug Administration (FDA) for other types of tumors, it is not approved by the FDA for treatment of NF2 related tumors.

Description:

This protocol is a Phase II, open-label, efficacy and safety study of single-agent RAD001 in patients with NF2. During the study, subjects will receive continuous daily oral treatment with RAD001 for up to 1 year or until tumor progression. Primary Objective: To determine whether RAD001 has an effect on the VS growth in patients with NF2 at a rate sufficient to submit the drug for further testing. Secondary Objectives: To determine whether RAD001 has an effect on the volume of other intracranial tumors, and to assess the effect of RAD001 on hearing function in patients with NF2 (when applicable).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: February 6, 2024
• Est. primary completion date: February 6, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 65 Years

Eligibility

Inclusion Criteria:

• Diagnosis of NF2 by National Institutes of Health (NIH) criteria
• Age = 16 years
• Progressive VS growth during the previous 12 months.
• WHO performance status > or = 2
• Adequate bone marrow, liver and renal function.
• For women of childbearing potential, no pregnancy or breast-feeding
• Willingness and ability to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.
• Willingness to provide informed consent

Exclusion Criteria:

• Inability to tolerate periodic MRI scans or gadolinium contrast.
• Inability to tolerate periodic audiologic testing or to understand a language with established scoring for word recognition testing.
• Inability to adequately perform volumetric measurement of at least 1 target lesionNote: Patients with cochlear or auditory brainstem implants may participate if a target lesion can be accurately assessed.
• Radiation therapy for the target lesion in the 60 months preceding inclusion in the study.
• Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug.
• Immunization with attenuated live vaccines within one week of study entry or during study period.
• Presence of a fungal infection requiring systemic antifungal treatment at enrollment
• Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin.
• Patients who have any severe and/or uncontrolled medical conditions.
• Patients with a known hypersensitivity to everolimus or other types of rapamycin or to its excipients.
• Patients unwilling to or unable to comply with the protocol

Related Conditions & MeSH terms

• Neurilemmoma
• Neurofibroma
• Neurofibromatoses
• Neurofibromatosis 1
• Neurofibromatosis 2
• Neurofibromatosis Type 2
• Neuroma
• Neuroma, Acoustic

Intervention

Drug:
• RAD001, everolimus
Adults: 10 mg p.o. daily dose, age 16 - 17: 3.0 mg/m2 p.o. daily

Locations

Country	Name	City	State
United States	University of California Los Angeles	Los Angeles	California

Sponsors (2)

Lead Sponsor	Collaborator
Jonsson Comprehensive Cancer Center	Novartis Pharmaceuticals

Country where clinical trial is conducted

United States, 

References & Publications (2)

Giovannini M, Bonne NX, Vitte J, Chareyre F, Tanaka K, Adams R, Fisher LM, Valeyrie-Allanore L, Wolkenstein P, Goutagny S, Kalamarides M. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. Neuro Oncol. 2014 Apr;16(4):493-504. doi: 10.1093/neuonc/not242. Epub 2014 Jan 10. — View Citation

Goutagny S, Raymond E, Esposito-Farese M, Trunet S, Mawrin C, Bernardeschi D, Larroque B, Sterkers O, Giovannini M, Kalamarides M. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neurooncol. 2015 Apr;122(2):313-20. doi: 10.1007/s11060-014-1710-0. Epub 2015 Jan 8. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Vestibular schwannoma volume	Determine the effect of RAD001 on change in vestibular schwannoma volume (mm3) by MRI from baseline to 1 year.	1 year (12 months)
Secondary	Hearing	Determine the effects of RAD001 treatment on hearing changes (from baseline to 1 year in the ear with the growing vestibular schwannoma.	1 year (12 months)
Secondary	Number of adverse events	Determine the number of study subjects with adverse events by grade of severity	1 year, 1 month (13 months)